Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pioglitazone and Empagliflozin in Type 2 Diabetes and NAFLD
NCT04976283Phase 4Unknown
- Sponsor
- Getz Pharma
- Start
- Sep 2021
- Primary completion
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of pioglitazone and empagliflozin in type 2 diabetes mellitus (T2DM), Nonalcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD) (3 arms), sponsored by Getz Pharma. Status: unknown.
02
Drugs
pioglitazoneempagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)Nonalcoholic steatohepatitis (NASH)non-alcoholic fatty liver disease (NAFLD)
Beyond the preview
Go deeper on NCT04976283.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04976283.